CEO Søren Bregenholt participated at the Redeye Life Science Day on November 24th.
Click here for a link to the InFocus interview.
LATEST NEWS
Data presented on mitazalimab and ATOR-1017 in Two Poster Presentations at SITC Annual Meeting 2022 – November 8-12, 2022
Mitazalimab data show the CD40 agonist induces strong immune responses in patients with advanced stage solid tumors and further strengthens …
Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics
ALG.APV-527 Demonstrates Favorable Preclinical Efficacy and Safety Compared to a First Generation 4-1BB Antibody ALG.APV-527 Rapidly Progres …
Alligator Bioscience Announces IND Approval for Second Phase 2 Clinical Trial of AC101 (HLX22) in Gastric Cancer developed by Shanghai Henlius Biotech in China
Study to evaluate AC101 (HLX22) in combination with anti-PD-1 antibody serplulimab, trastuzumab and chemotherapy in gastric cancer Phase 2 c …